Current Value
$23.651 Year Return
Current Value
$23.651 Year Return
Double maintains 1 strategies that include ANAB - AnaptysBio, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SMWB | -16.93% | $704.05M | +14.71% | 0.00% |
| OMCL | -11.95% | $1.40B | +11.36% | 0.00% |
| RDDT | -11.92% | $29.40B | +116.44% | 0.00% |
| GRMN | -10.27% | $41.09B | +32.42% | 1.47% |
| PSQH | -9.24% | $98.82M | -36.55% | 0.00% |
| STG | -8.89% | $30.78M | -22.51% | 0.00% |
| WST | -8.09% | $15.89B | -31.06% | 0.37% |
| JKHY | -7.52% | $13.06B | +9.64% | 1.26% |
| MODV | -6.30% | $45.07M | -88.46% | 0.00% |
| TRVG | -6.28% | $86.72M | +88.56% | 0.00% |
| CNC | -6.12% | $16.81B | -49.40% | 0.00% |
| MOH | -6.06% | $12.95B | -19.36% | 0.00% |
| GFI | -5.88% | $21.56B | +57.55% | 2.31% |
| DRD | -5.77% | $1.18B | +51.33% | 2.03% |
| ATOM | -5.76% | $152.60M | +28.42% | 0.00% |
| PRPO | -5.54% | $17.08M | +125.94% | 0.00% |
| MSIF | -5.42% | $769.47M | +36.17% | 7.61% |
| CRK | -5.24% | $7.28B | +127.56% | 0.00% |
| DFDV | -5.01% | $300.56M | +2,130.16% | 0.00% |
| OSCR | -4.90% | $4.23B | -2.64% | 0.00% |
Finnhub
Presenter SpeechUnknown Analyst All right. Good morning, and it's my pleasure to introduce Dan Faga, President and CEO of AnaptysBio as our next speaker. Dan, welcome. It's the first time for me to...
SeekingAlpha
AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is secured. Read at what price ANAB is a Buy.
SeekingAlpha
AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.
Finnhub
Jefferies Global Healthcare Conference June 2025 ...
Yahoo
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared to standard of care biologics or JAKsMax response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50Durable responses for at least two months off drug, with
Finnhub
Presentation Operator MessageOperator Good day and thank you for standing by. Welcome to the Rosnilimab Updated Phase IIb Rheumatoid Arthritis Data Update. [Operator Instructions] Please be advised...
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GOVZ | -0.01% | $272.00M | 0.1% |
| BILS | 0.01% | $3.81B | 0.1356% |
| FTGC | 0.01% | $2.39B | 0.98% |
| BCI | 0.04% | $1.58B | 0.26% |
| FLMI | 0.07% | $725.99M | 0.3% |
| FTSD | 0.08% | $231.81M | 0.25% |
| IBMP | 0.11% | $553.65M | 0.18% |
| TBIL | -0.15% | $5.81B | 0.15% |
| HYD | 0.17% | $3.32B | 0.32% |
| ITM | 0.24% | $1.87B | 0.18% |
| BIL | -0.24% | $42.24B | 0.1356% |
| CLIP | 0.25% | $1.51B | 0.07% |
| HTAB | 0.30% | $411.35M | 0.39% |
| SPTS | 0.42% | $5.80B | 0.03% |
| BUXX | 0.48% | $315.18M | 0.25% |
| DFNM | -0.50% | $1.57B | 0.17% |
| ULST | 0.53% | $654.75M | 0.2% |
| XONE | 0.60% | $625.28M | 0.03% |
| PWZ | 0.62% | $759.91M | 0.28% |
| CMDY | -0.62% | $267.28M | 0.28% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 37.80% | $4.82B | 0.35% |
| PTH | 35.42% | $100.85M | 0.6% |
| GNOM | 35.27% | $44.57M | 0.5% |
| ARKG | 34.96% | $1.02B | 0.75% |
| IWC | 33.38% | $818.14M | 0.6% |
| IBB | 33.01% | $5.26B | 0.45% |
| PINK | 31.58% | $130.57M | 0.5% |
| PBE | 31.32% | $223.19M | 0.58% |
| IWO | 29.66% | $11.60B | 0.24% |
| PSC | 29.10% | $752.65M | 0.38% |
| XPH | 29.01% | $147.96M | 0.35% |
| VTWO | 28.99% | $12.52B | 0.07% |
| IWM | 28.79% | $63.72B | 0.19% |
| FFTY | 28.13% | $81.20M | 0.8% |
| BBH | 27.92% | $330.62M | 0.35% |
| GSSC | 27.92% | $561.54M | 0.2% |
| KJUL | 27.90% | $119.50M | 0.79% |
| FYX | 27.60% | $817.02M | 0.6% |
| IWN | 27.45% | $10.96B | 0.24% |
| FBT | 27.40% | $1.01B | 0.54% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLDX | 36.36% | $1.47B | -38.43% | 0.00% |
| CHEF | 36.21% | $2.58B | +55.30% | 0.00% |
| GIC | 36.20% | $1.08B | -9.65% | 3.61% |
| AGIO | 36.08% | $2.05B | -15.87% | 0.00% |
| AVNS | 35.58% | $572.50M | -36.25% | 0.00% |
| SPRY | 35.51% | $1.65B | +84.27% | 0.00% |
| ENTA | 34.96% | $170.37M | -39.35% | 0.00% |
| PLRX | 34.87% | $73.66M | -88.66% | 0.00% |
| NRIX | 34.87% | $948.37M | -35.91% | 0.00% |
| BLKB | 34.61% | $3.15B | -14.51% | 0.00% |
| ZYME | 33.73% | $905.57M | +53.64% | 0.00% |
| CVS | 33.72% | $84.25B | +17.46% | 3.97% |
| QTTB | 33.55% | $17.56M | -91.69% | 0.00% |
| APGE | 33.17% | $2.64B | +18.19% | 0.00% |
| NERV | 33.05% | $12.10M | -44.91% | 0.00% |
| CRSP | 32.94% | $4.46B | -4.14% | 0.00% |
| PGEN | 32.58% | $475.24M | +9.52% | 0.00% |
| OCUL | 32.35% | $1.51B | +41.41% | 0.00% |
| STHO | 31.92% | $104.69M | -31.17% | 0.00% |
| OPCH | 31.84% | $5.08B | +15.10% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -16.95% | $164.54M | 0.85% |
| TAIL | -16.09% | $99.63M | 0.59% |
| BTAL | -16.08% | $296.22M | 1.43% |
| USDU | -8.30% | $162.43M | 0.5% |
| UUP | -7.78% | $201.63M | 0.77% |
| PSQA | -6.72% | $35.44M | 0.2% |
| UNG | -6.62% | $360.54M | 1.06% |
| DBE | -6.60% | $52.20M | 0.77% |
| CMBS | -6.07% | $449.66M | 0.25% |
| UGA | -5.80% | $72.33M | 0.97% |
| USL | -5.58% | $42.23M | 0.85% |
| BNO | -4.91% | $103.79M | 1% |
| PDBC | -4.89% | $4.42B | 0.59% |
| OILK | -4.77% | $71.87M | 0.69% |
| DBC | -4.68% | $1.23B | 0.87% |
| USO | -4.53% | $1.13B | 0.6% |
| COM | -4.53% | $207.38M | 0.72% |
| DBO | -4.33% | $228.24M | 0.77% |
| JUCY | -4.29% | $269.70M | 0.6% |
| MMIN | -3.81% | $336.10M | 0.3% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VZ | -0.01% | $183.79B | +6.01% | 6.18% |
| KO | -0.02% | $305.22B | +11.97% | 2.81% |
| PEN | -0.02% | $9.67B | +40.76% | 0.00% |
| LRN | 0.03% | $5.99B | +100.06% | 0.00% |
| AEP | -0.06% | $55.16B | +17.93% | 3.54% |
| NRDS | 0.06% | $845.72M | -25.43% | 0.00% |
| RLMD | 0.07% | $19.95M | -80.03% | 0.00% |
| ABBV | 0.07% | $336.94B | +16.42% | 3.35% |
| CHRW | 0.07% | $11.77B | +13.29% | 2.48% |
| K | 0.07% | $27.76B | +41.17% | 2.85% |
| TR | 0.10% | $2.57B | +22.68% | 1.02% |
| RRC | 0.11% | $9.27B | +12.72% | 0.87% |
| EXAS | -0.12% | $10.16B | +24.70% | 0.00% |
| CTRA | 0.13% | $19.10B | -6.92% | 3.40% |
| GIS | -0.14% | $29.20B | -14.66% | 4.47% |
| TTWO | 0.16% | $42.50B | +56.03% | 0.00% |
| DXCM | 0.16% | $32.77B | -24.64% | 0.00% |
| SHAK | -0.18% | $5.68B | +64.45% | 0.00% |
| INFA | -0.18% | $7.38B | -20.07% | 0.00% |
| GRFS | -0.22% | $2.36B | +37.65% | 0.00% |
